There was also an equal frequency distribution of the four main WHO subtypes (i.e., AML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-related AML, and AML not otherwise specified [18]) among the total patient population and the BCL-2−/BCL-2+ subgroups. This evidence concerns the gene BCL2 and acute myeloid leukemia.